ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 168 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2017. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $7,744,000 | -22.2% | 217,236 | +0.7% | 0.01% | -9.1% |
Q2 2023 | $9,949,000 | -73.9% | 215,668 | -77.3% | 0.01% | -75.6% |
Q1 2023 | $38,143,000 | -27.4% | 951,190 | -16.1% | 0.04% | -27.4% |
Q4 2022 | $52,511,000 | +13.2% | 1,133,412 | +1.3% | 0.06% | +8.8% |
Q3 2022 | $46,384,000 | -30.0% | 1,119,395 | +0.8% | 0.06% | -23.0% |
Q2 2022 | $66,256,000 | -15.4% | 1,110,561 | +3.0% | 0.07% | +23.3% |
Q1 2022 | $78,287,000 | +0.7% | 1,078,024 | +16.6% | 0.06% | -7.7% |
Q4 2021 | $77,714,000 | -7.5% | 924,172 | -0.8% | 0.06% | -9.7% |
Q3 2021 | $83,991,000 | -5.7% | 931,269 | -0.3% | 0.07% | -1.4% |
Q2 2021 | $89,026,000 | -23.8% | 933,677 | -9.0% | 0.07% | -55.8% |
Q1 2021 | $116,768,000 | -27.7% | 1,025,539 | -12.1% | 0.16% | -30.1% |
Q4 2020 | $161,501,000 | +44.2% | 1,166,661 | -14.4% | 0.24% | +24.2% |
Q3 2020 | $111,972,000 | -6.3% | 1,362,353 | -10.8% | 0.19% | -7.8% |
Q2 2020 | $119,443,000 | +65.7% | 1,527,015 | -5.9% | 0.21% | +39.2% |
Q1 2020 | $72,087,000 | +19.3% | 1,622,502 | +14.7% | 0.15% | +72.1% |
Q4 2019 | $60,401,000 | +14.2% | 1,414,209 | +14.4% | 0.09% | -3.4% |
Q3 2019 | $52,877,000 | -65.2% | 1,236,013 | -48.3% | 0.09% | +3.5% |
Q2 2019 | $151,884,000 | +228.4% | 2,391,879 | +258.7% | 0.09% | +8.9% |
Q1 2019 | $46,244,000 | +198.6% | 666,732 | +87.2% | 0.08% | +163.3% |
Q4 2018 | $15,487,000 | -22.7% | 356,202 | +35.7% | 0.03% | -9.1% |
Q3 2018 | $20,045,000 | +2110.0% | 262,577 | +1935.5% | 0.03% | +1550.0% |
Q4 2016 | $907,000 | -13.0% | 12,900 | -12.2% | 0.00% | 0.0% |
Q3 2016 | $1,043,000 | -8.8% | 14,700 | -37.2% | 0.00% | +100.0% |
Q2 2016 | $1,144,000 | -61.2% | 23,400 | -49.8% | 0.00% | -83.3% |
Q1 2016 | $2,952,000 | -53.4% | 46,633 | -17.4% | 0.01% | -53.8% |
Q4 2015 | $6,332,000 | +31.0% | 56,442 | +12.5% | 0.01% | +30.0% |
Q3 2015 | $4,833,000 | -17.7% | 50,184 | -12.5% | 0.01% | -16.7% |
Q2 2015 | $5,871,000 | +226.0% | 57,337 | +97.7% | 0.01% | +200.0% |
Q1 2015 | $1,801,000 | +315.9% | 29,000 | +194.1% | 0.00% | +300.0% |
Q4 2014 | $433,000 | -22.4% | 9,862 | 0.0% | 0.00% | 0.0% |
Q3 2014 | $558,000 | +26.0% | 9,862 | 0.0% | 0.00% | 0.0% |
Q2 2014 | $443,000 | -8.1% | 9,862 | 0.0% | 0.00% | 0.0% |
Q1 2014 | $482,000 | – | 9,862 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |